A comprehensive view of Injectables/Infusions/IV Drips. This page highlights a small sample of our full coverage.
For real-time access, please log in to your R&D/Patents Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Canada to buy 15,000 treatment courses of Roche’s Actemra IV tocilizumab injectable to treat adult patients hospitalized with COVID-19; an estimated 429 out of 1,000 patients hospitalized with COVID-19 are eligible for tocilizumab

FDA withdraws emergency use authorization of Eli Lilly’s bebtelovimab injectable COVID-19 antibody therapy, citing the therapy is most likely ineffective against Omicron BQ.1 and BQ.1.1; Lilly had supplied 60,000 doses of the drug to US government in Q3

Roche receives Canadian approval for injectable Polivy polatuzumab vedotin to treat B-cell lymphoma; drug used in combination with Rituxan rituximab, cyclophosphamide, doxorubicin and immunosuppressive drug prednisone

FDA approves Dutch biotech firm UniQure’s Hemgenix injectable to treat hemophilia B, making it the first gene therapy treatment for the disorder; Australian drugmaker CSL has license for the treatment and places list price at US$3.5M

Eli Lilly lists a new clinical trial to study of injectable LY3305677 in participants with obesity or overweight

Ask us about our R&D/Patents market view

Trending Chart

Interactive chart with headline count